KR20030084887A - 안정성이 증강된 면역원성 HBc 키머 입자 - Google Patents
안정성이 증강된 면역원성 HBc 키머 입자 Download PDFInfo
- Publication number
- KR20030084887A KR20030084887A KR10-2003-7002259A KR20037002259A KR20030084887A KR 20030084887 A KR20030084887 A KR 20030084887A KR 20037002259 A KR20037002259 A KR 20037002259A KR 20030084887 A KR20030084887 A KR 20030084887A
- Authority
- KR
- South Korea
- Prior art keywords
- hbc
- residues
- amino acid
- sequence
- residue
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 381
- 230000002163 immunogen Effects 0.000 title claims abstract description 117
- 241000251204 Chimaeridae Species 0.000 title claims description 55
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 100
- 238000000034 method Methods 0.000 claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 266
- 125000000539 amino acid group Chemical group 0.000 claims description 205
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 154
- 102000004169 proteins and genes Human genes 0.000 claims description 143
- 235000018102 proteins Nutrition 0.000 claims description 141
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 138
- 230000014509 gene expression Effects 0.000 claims description 96
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 88
- 125000005647 linker group Chemical group 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 83
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 76
- 229960005486 vaccine Drugs 0.000 claims description 72
- 150000007523 nucleic acids Chemical class 0.000 claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 61
- 235000018417 cysteine Nutrition 0.000 claims description 59
- 102000039446 nucleic acids Human genes 0.000 claims description 58
- 108020004707 nucleic acids Proteins 0.000 claims description 58
- 108020001507 fusion proteins Proteins 0.000 claims description 56
- 102000037865 fusion proteins Human genes 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 56
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 54
- 241000588724 Escherichia coli Species 0.000 claims description 49
- 150000001413 amino acids Chemical group 0.000 claims description 48
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 44
- 239000002671 adjuvant Substances 0.000 claims description 42
- 241001465754 Metazoa Species 0.000 claims description 37
- 239000002054 inoculum Substances 0.000 claims description 30
- 208000002672 hepatitis B Diseases 0.000 claims description 27
- 238000002835 absorbance Methods 0.000 claims description 25
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 22
- 239000004472 Lysine Substances 0.000 claims description 22
- 235000018977 lysine Nutrition 0.000 claims description 22
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 21
- 230000000295 complement effect Effects 0.000 claims description 20
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000839 emulsion Substances 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 230000036039 immunity Effects 0.000 claims description 10
- 235000003704 aspartic acid Nutrition 0.000 claims description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
- 239000004220 glutamic acid Substances 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 8
- -1 fatty acid esters Chemical class 0.000 claims description 8
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 7
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 239000012071 phase Substances 0.000 claims description 7
- 229940031439 squalene Drugs 0.000 claims description 7
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 229940032094 squalane Drugs 0.000 claims description 6
- 241000606768 Haemophilus influenzae Species 0.000 claims description 4
- 241001580565 Peachia Species 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 238000001338 self-assembly Methods 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 3
- 241000223960 Plasmodium falciparum Species 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 150000003384 small molecules Chemical group 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- RYELXWKWBUDRKN-UMMCILCDSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-oxo-3h-purine-8-sulfonic acid Chemical class OS(=O)(=O)C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RYELXWKWBUDRKN-UMMCILCDSA-N 0.000 claims description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 2
- 241000223830 Plasmodium yoelii Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000000893 inhibin Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims 6
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 3
- 241000224016 Plasmodium Species 0.000 claims 3
- 229910052703 rhodium Inorganic materials 0.000 claims 3
- 239000010948 rhodium Substances 0.000 claims 3
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 241000737598 recombinant Hepatitis B virus Species 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- QLRRUWXMMVXORS-UHFFFAOYSA-N Augustine Natural products C12=CC=3OCOC=3C=C2CN2C3CC(OC)C4OC4C31CC2 QLRRUWXMMVXORS-UHFFFAOYSA-N 0.000 claims 1
- 241000223936 Cryptosporidium parvum Species 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000224432 Entamoeba histolytica Species 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 241000223810 Plasmodium vivax Species 0.000 claims 1
- 241000605862 Porphyromonas gingivalis Species 0.000 claims 1
- 241000242677 Schistosoma japonicum Species 0.000 claims 1
- 241000242680 Schistosoma mansoni Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 claims 1
- 241000193987 Streptococcus sobrinus Species 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 229940007078 entamoeba histolytica Drugs 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 abstract description 11
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract description 10
- 102000053602 DNA Human genes 0.000 description 70
- 108020004414 DNA Proteins 0.000 description 67
- 241000196324 Embryophyta Species 0.000 description 62
- 239000013612 plasmid Substances 0.000 description 58
- 239000012634 fragment Substances 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 38
- 238000003752 polymerase chain reaction Methods 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 36
- 108010078791 Carrier Proteins Proteins 0.000 description 35
- 108020004705 Codon Proteins 0.000 description 35
- 239000000562 conjugate Substances 0.000 description 31
- 238000001990 intravenous administration Methods 0.000 description 31
- 241000700605 Viruses Species 0.000 description 29
- 239000013604 expression vector Substances 0.000 description 29
- 238000003780 insertion Methods 0.000 description 27
- 230000037431 insertion Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 230000009261 transgenic effect Effects 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 23
- 230000005847 immunogenicity Effects 0.000 description 23
- 210000000056 organ Anatomy 0.000 description 23
- 239000013615 primer Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 19
- 150000004676 glycans Chemical class 0.000 description 18
- 239000000178 monomer Substances 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 229920001282 polysaccharide Polymers 0.000 description 17
- 239000005017 polysaccharide Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 230000003053 immunization Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 16
- 101710132601 Capsid protein Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 201000004792 malaria Diseases 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 108020004511 Recombinant DNA Proteins 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 230000000087 stabilizing effect Effects 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000007771 core particle Substances 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
- 239000013600 plasmid vector Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 150000003839 salts Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108020005029 5' Flanking Region Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 241000555745 Sciuridae Species 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 235000002374 tyrosine Nutrition 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- TWLQEIBUXHHZPI-UPPQRMANSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]p Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2[C@@H](CCC2)C(O)=O)CCC1 TWLQEIBUXHHZPI-UPPQRMANSA-N 0.000 description 4
- NNLZBVFSCVTSLA-HXUQBWEZSA-N 3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid Chemical compound OC[C@@H](O)[C@H]1O[C@@](O)(C(O)=O)C[C@@H](O)[C@H]1O NNLZBVFSCVTSLA-HXUQBWEZSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 241000283923 Marmota monax Species 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- 241001460678 Napo <wasp> Species 0.000 description 4
- 101150053185 P450 gene Proteins 0.000 description 4
- 101710182846 Polyhedrin Proteins 0.000 description 4
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 4
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 231100000676 disease causative agent Toxicity 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 241000701489 Cauliflower mosaic virus Species 0.000 description 3
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 3
- 241001647372 Chlamydia pneumoniae Species 0.000 description 3
- 244000241257 Cucumis melo Species 0.000 description 3
- 101150070004 E8 gene Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KGVHCTWYMPWEGN-FSPLSTOPSA-N Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CN KGVHCTWYMPWEGN-FSPLSTOPSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000700739 Hepadnaviridae Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- KRBIJIBTUCNJGU-BLADHDKVSA-N OP(O)(O)=O.OC[C@H](O)[C@H](O)[C@H](O)CO.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H](O)[C@H](O)CO.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O KRBIJIBTUCNJGU-BLADHDKVSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101710091688 Patatin Proteins 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004520 cell wall skeleton Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 108010025188 Alcohol oxidase Proteins 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001203868 Autographa californica Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 2
- 235000004936 Bromus mango Nutrition 0.000 description 2
- 101800000655 C-terminal peptide Proteins 0.000 description 2
- 102400000107 C-terminal peptide Human genes 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 210000000712 G cell Anatomy 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 235000014826 Mangifera indica Nutrition 0.000 description 2
- 240000007228 Mangifera indica Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000009188 Phyllostachys vivax Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 235000009184 Spondias indica Nutrition 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241001002356 Valeriana edulis Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021022 fresh fruits Nutrition 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 150000002298 globosides Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- CYNAPIVXKRLDER-LBPRGKRZSA-N (2s)-2-benzamido-3-(4-hydroxy-3-nitrophenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C([N+]([O-])=O)=C1 CYNAPIVXKRLDER-LBPRGKRZSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CUCJJMLDIUSNPU-UHFFFAOYSA-N 1-oxidopiperidin-1-ium Chemical compound [O-][NH+]1CCCCC1 CUCJJMLDIUSNPU-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- MNQVNFIVCSQNGY-FHAQVOQBSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O MNQVNFIVCSQNGY-FHAQVOQBSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
- 101150061183 AOX1 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 101710109085 Cysteine synthase, chloroplastic/chromoplastic Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical group 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- VJDOAZKNBQCAGE-LMVFSUKVSA-N D-ribitol 5-phosphate Chemical compound OC[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O VJDOAZKNBQCAGE-LMVFSUKVSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical group S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000700735 Ground squirrel hepatitis virus Species 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000941690 Homo sapiens Cytochrome P450 1A1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 150000007649 L alpha amino acids Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 241000984622 Leucodon Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 206010053584 Neonatal pneumonia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710156615 Sucrose synthase 1 Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101710109576 Terminal protein Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000255985 Trichoplusia Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 125000001488 beta-D-galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- KGVHCTWYMPWEGN-UHFFFAOYSA-N glycyl-isoleucine Chemical group CCC(C)C(C(O)=O)NC(=O)CN KGVHCTWYMPWEGN-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000052268 human CYP1A1 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000007529 inorganic bases Chemical group 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical compound CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- UTOPWMOLSKOLTQ-UHFFFAOYSA-M octacosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC([O-])=O UTOPWMOLSKOLTQ-UHFFFAOYSA-M 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000027086 plasmid maintenance Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000005562 seed maturation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
화학적 합텐 | 인용문헌 |
피페리딘 N-옥사이드 | 미국 특허 제5,304,252호 |
포스포락톤 또는 락타미드 | 미국 특허 제5,248,611호 |
금속 이온 착체 | 미국 특허 제5,236,825호 |
[2.2.1] 또는 [7.2.2]바이사이클릭 환 화합물 | 미국 특허 제5,208,152호 |
이온으로 하전된하이드록실-함유 화합물 | 미국 특허 제5,187,086호 |
카복실레이트 에스테르의포스포네이트 동족체 | 미국 특허 제5,126,258호 |
코카인 동족체 | Carrera et al., (1995) Nature 378:725 |
Claims (115)
- (a) HBc 면역우성 루프에 존재하는 접합된 에피토프에 대한 이종 링커 잔기 또는 펩티드-결합된 이종 에피토프를 포함하는 HBc 분자의 N-말단의 150개 아미노산 잔기중 약 130개 이상의 HBc 서열, 또는 N-말단의 150개 HBc 아미노산 잔기중 약 135개 이상의 잔기 서열을 함유하고,(b) HBc 서열의 C-말단 잔기로부터 상기 분자의 C-말단을 향하고 있고 키머 분자의 C-말단으로부터 약 30개 잔기 내에 존재하는 1 내지 10개의 시스테인 잔기[C-말단 시스테인 잔기(들)]를 함유하며,(c) HBc 위치 135에서부터 HBc C-말단까지의 5개 이상의 아미노산 잔기 서열을 함유하는, 길이가 약 515개 이하의 아미노산 잔기이고;(i) HBc 서열 내의 20% 이하의 보존적으로 치환된 아미노산 잔기를 함유하고, (ii) 숙주 세포에서의 발현시, 핵산과 실질적으로 결합하지 않는 입자 내로 자기-어셈블리되는데, 이러한 입자가 상기 C-말단 시스테인 잔기(들)가 결여되고 그 밖에는 동일한 HBc 키머로부터 형성된 입자 보다 더 안정적이거나 또는 키머 분자에 존재하는 하나의 C-말단 시스테인 잔기가 또 다른 잔기로 대체된 경우 보다 더 안정적인, 재조합 키머 B형 간염 코어(HBc) 단백질 분자.
- 제1항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기 또는 펩티드-결합된 이종 에피토프가 이종 에피토프인 재조합 HBc 키머 단백질 분자.
- 제2항에 있어서, 이종 에피토프가 B 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제3항에 있어서, HBc의 아미노산 잔기 1-4 중의 하나와 펩티드-결합된 제2의 이종 에피토프를 함유하는 재조합 HBc 키머 단백질 분자.
- 제3항에 있어서, B 세포 에피토프가 HBc 서열 내의 아미노산 잔기 76 내지 85의 위치에서 펩티드-결합되고, 위치 76에서부터 85까지의 HBc 서열의 5개 이상의 잔기가 존재하는 재조합 HBc 키머 단백질 분자.
- 제5항에 있어서, B 세포 에피토프에 의해 중단된 아미노산 잔기 76 내지 85의 HBc 서열이 존재하는 재조합 HBc 키머 단백질 분자.
- 제2항에 있어서, 펩티드-결합된 이종 T 세포 에피토프를 추가로 포함하는 재조합 HBc 키머 단백질 분자.
- 제7항에 있어서, T 세포 에피토프가 C-말단 HBc 아미노산 잔기와 펩티드-결합되는 재조합 HBc 키머 단백질 분자.
- 제8항에 있어서, C-말단 시스테인 잔기(들)가, 당해 HBc 키머 단백질 분자의 C-말단의 5개 아미노산 잔기 이내에 존재하는 재조합 HBc 키머 단백질 분자.
- 제1항에 있어서, 키머가 위치 1에서부터 적어도 위치 140까지의 중단되지 않은 HBc 아미노산 잔기 서열 + 당해 HBc 키머 단백질 분자의 C-말단에서의 하나의 시스테인 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제10항에 있어서, 키머가 위치 1에서부터 위치 149까지의 중단되지 않은 HBc 아미노산 잔기 서열을 함유하는 재조합 HBc 키머 단백질 분자.
- 제1항에 있어서, 키머가 접합된 에피토프에 대한 이종 링커 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제12항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기가 HBc 서열 내의 아미노산 잔기 76 내지 85의 위치에서 펩티드-결합되고, 위치 76에서부터 85까지의 HBc 서열의 4개 이상의 잔기가 존재하는 재조합 HBc 키머 단백질 분자.
- 제13항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기에 의해 중단된 아미노산 잔기 76 내지 85의 HBc 서열이 존재하는 재조합 HBc 키머 단백질 분자.
- 제14항에 있어서, 위치 1에서부터 적어도 위치 140까지의 HBc 아미노산 잔기 서열 + C-말단에서의 단일 시스테인 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제15항에 있어서, 키머가 위치 1에서부터 위치 149까지의 HBc 아미노산 잔기 서열을 함유하는 재조합 HBc 키머 단백질 분자.
- 제16항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기가 리신, 아스파르트산, 글루탐산, 시스테인 및 티로신 잔기로 이루어진 그룹 중에서 선택되는 재조합 HBc 키머 단백질 분자.
- 도메인 I, II, III 및 IV로 명명된, N-말단으로부터 4개의 펩티드-연결된 아미노산 잔기 서열 도메인을 함유하는 약 135 내지 약 515개 아미노산 잔기 길이를 가지며, 이때(a) 도메인 I은 약 71 내지 약 100개 아미노산 잔기를 포함하는데, 이의 서열에는 적어도 HBc의 위치 5에서부터 위치 75까지의 잔기 서열이 포함되고, HBc 잔기 1 내지 4 중의 하나와 펩티드-결합된 약 30개 이하의 아미노산 잔기를 함유하는 이종 에피토프가 임의로 포함되고;(b) 도메인 II는 도메인 I의 HBc 잔기 75와 펩티드-결합된 약 5 내지 약 250개 아미노산 잔기를 포함하는데, 여기서 (i) HBc 위치 76에서부터 85까지의 서열내의 0 내지 모든 잔기는, HBc와 이종이고 접합된 에피토프에 대한 이종 링커 잔기 또는 이종 에피토프를 구성하는 1 내지 약 245개 아미노산 잔기와 펩티드-결합되어 존재하거나, (ii) 위치 75 내지 85에서의 HBc 서열에는 이종 잔기가 전혀 존재하지 않거나, 또는 (iii) 잔기 76 내지 85 중의 하나 이상이 존재하지 않으며;(c) 도메인 III은 도메인 II의 잔기 85와 펩티드-결합된 위치 86에서부터 위치 135까지의 HBc 서열이고;(d) 도메인 IV는 (i) 도메인 III의 위치 135의 잔기와 펩티드-결합된 위치 136에서부터 149까지의 HBc 아미노산 잔기 서열의 0 내지 14개 잔기; (ii) 키머 분자의 C-말단으로부터 약 30개 잔기 이내의 1 내지 10개의 시스테인 잔기[C-말단 시스테인 잔기(들)]; 및 (iii) 위치 150에서부터 C-말단까지의 HBc와 이종인 서열 내의 0 내지 약 100개 아미노산 잔기를 포함하는데, 단 도메인 IV는 상기 (ii)의 1 내지 10개 시스테인 잔기를 포함한 6개 이상의 아미노산 잔기를 함유하고;숙주 세포에서의 발현시 입자 내로 자기-어셈블리되는데, 상기 입자는 핵산과 실질적으로 결합하지 않고, 상기 C-말단 시스테인 잔기(들)가 결여되고 그 밖에는 동일한 HBc 키머로부터 형성된 입자 보다 안정적이거나 또는 키머 분자 내에 존재하는 하나의 C-말단 시스테인 잔기가 또 다른 잔기로 대체된 경우 보다 더 안정적이고, 아미노산 잔기의 10% 이하가 키머의 HBc 서열에서 치환된 아미노산 잔기 서열을 갖는, 재조합 B형 간염 바이러스 코어(HBc) 키머 단백질 분자.
- 제18항에 있어서, 2개의 이종 에피토프를 함유하는 재조합 HBc 키머 단백질분자.
- 제19항에 있어서, 2개의 이종 에피토프가 도메인 I 및 II, II 및 IV 또는 I 및 IV에 존재하는 재조합 HBc 키머 단백질 분자.
- 제19항에 있어서, 2개의 이종 에피토프 중의 하나가 B 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제19항에 있어서, 2개의 이종 에피토프 중의 하나가 T 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제19항에 있어서, 2개의 이종 에피토프 중의 하나가 B 세포 에피토프이고, 다른 하나가 T 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제18항에 있어서, 도메인 I에는, HBc 잔기 1-4 중의 하나와 펩티드-결합된 이종 에피토프가 포함되는 재조합 HBc 키머 단백질 분자.
- 제24항에 있어서, 도메인 II의 이종 에피토프가 B 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제25항에 있어서, 위치 150에서부터 C-말단까지의 HBc와 이종인 서열이 HBc 잔기 140-149 중의 하나와 펩티드-결합된 T 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제18항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기 또는 이종 에피토프가 이종 에피토프인 재조합 HBc 키머 단백질 분자.
- 제27항에 있어서, 이종 에피토프가 약 245개 이하의 아미노산 잔기를 포함하는 재조합 HBc 키머 단백질 분자.
- 제28항에 있어서, 이종 에피토프가 B 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제27항에 있어서, 이종 에피토프가 6 내지 약 50개 아미노산 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제27항에 있어서, 이종 에피토프가 20 내지 약 30개 아미노산 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제27항에 있어서, 도메인 IV가, 키머 분자의 C-말단으로부터 약 30개 잔기이내에 1 내지 약 5개의 시스테인 잔기를 포함하는 재조합 HBc 키머 단백질 분자.
- 제27항에 있어서, 이종 에피토프에 의해 중단된 아미노산 잔기 76 내지 85의 HBc 서열이 존재하는 재조합 HBc 키머 단백질 분자.
- 제18항에 있어서, C-말단 시스테인 잔기가 키머 단백질 분자의 C-말단의 약 5개 아미노산 잔기 내에 위치하는 재조합 HBc 키머 단백질 분자.
- 제18항에 있어서, 위치 150에서부터 C-말단까지의 HBc와 이종인 서열이 HBc 잔기 140-149 중의 하나와 펩티드-결합된 T 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제18항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기 또는 이종 에피토프가 접합된 에피토프에 대한 이종 링커 잔기인 재조합 HBc 키머 단백질 분자.
- 제36항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기가 리신, 아스파르트산, 글루탐산, 시스테인 및 티로신 잔기로 이루어진 그룹 중에서 선택되는 재조합 HBc 키머 단백질 분자.
- 제37항에 있어서, HBc 키머 단백질 분자의 C-말단에서의 단일 시스테인 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제18항에 있어서, 키머가 적어도 위치 140까지의 중단되지 않은 HBc 아미노산 잔기 서열을 함유하는 재조합 HBc 키머 단백질 분자.
- 제39항에 있어서, 중단되지 않은 HBc 아미노산 잔기 서열에 잔기 1이 포함되는 재조합 HBc 키머 단백질 분자.
- 제39항에 있어서, 중단되지 않은 HBc 아미노산 잔기 서열에 잔기 149가 포함되는 재조합 HBc 키머 단백질 분자.
- 도메인 I, II, III 및 IV로 명명된, N-말단으로부터 4개의 펩티드-연결된 아미노산 잔기 서열 도메인을 함유하는 약 175 내지 약 240개 아미노산 잔기 길이를 가지며, 이때,(a) 도메인 I은 대략 HBc의 위치 1에서부터 위치 75까지의 잔기 서열을 포함하고;(b) 도메인 II는 도메인 I의 HBc 잔기 75와 펩티드-결합된 약 5 내지 약 55개 아미노산 잔기를 포함하는데, 여기서 HBc 위치 76에서부터 85까지의 서열 내의 4개 이상의 잔기가, HBc와 이종이고 이종 에피토프를 구성하는 6 내지 약 50개 아미노산 잔기와 펩티드-결합되어 존재하고;(c) 도메인 III은 도메인 II의 잔기 85와 펩티드-결합된 위치 86에서부터 위치 135까지의 HBc 서열이고;(d) 도메인 IV는 (i) 도메인 III의 위치 135의 잔기와 펩티드-결합된 위치 136에서부터 149까지의 HBc 아미노산 잔기 서열의 5 내지 14개 잔기, (ii) 키머 분자의 C-말단으로부터 약 30개 잔기 이내에 하나의 시스테인 잔기[C-말단 시스테인 잔기], 및 (iii) 위치 150에서부터 C-말단까지의 HBc와 이종인 서열 내의 0 내지 약 50개 아미노산 잔기를 포함하며;280nm 대 260nm의 흡광도 비가 약 1.2 내지 약 1.6인, 숙주 세포에서의 발현시 입자 내로 자기-어셈블리되는데, 상기 입자는 상기 C-말단 시스테인 잔기가 결여되고 그 밖에는 동일한 HBc 키머 분자로부터 형성된 입자 보다 안정적이거나 또는 키머 분자 내에 존재하는 하나의 C-말단 시스테인 잔기가 또 다른 잔기로 대체된 경우 보다 더 안정적이며, 또한 상기 입자가 아미노산 잔기의 약 5% 이하가 상기 키머의 HBc 서열에서 치환된 아미노산 잔기 서열을 갖는, 재조합 B형 간염 바이러스 코어(HBc) 키머 단백질 분자.
- 제42항에 있어서, 도메인 II의 이종 에피토프가 B 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제43항에 있어서, 이종 에피토프가 15 내지 약 50개 아미노산 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제43항에 있어서, 이종 에피토프가 20 내지 약 30개 아미노산 잔기를 함유하는 재조합 HBc 키머 단백질 분자.
- 제43항에 있어서, 이종 에피토프에 의해 중단된 아미노산 잔기 76 내지 85의 HBc 서열이 존재하는 재조합 HBc 키머 단백질 분자.
- 제43항에 있어서, B 세포 에피토프가 스트렙토코커스 뉴모니애(Streptococcus pneumonia),크립토스포리듐 파르붐(Cryptosporidium parvum),HIV, 구제역(foot-and-mouth disease) 바이러스, 인플루엔자 바이러스, 예르시니아 페스티스(Yersinia pestis),해모필루스 인플루엔자(Haemophilus influenzae),모락셀라 카타르할리스(Moraxella catarrhalis),포르피로모나스 긴기발리스(Porphyromonas gingivalis),트리파노소마 크루지(Trypanosoma cruzi), 플라스모듐 팔시파룸(Plasmodium falciparum),플라스모듐 비박스(Plasmodium vivax),플라스모듐 베르기(Plasmodium berghi),플라스모듐 요엘리(Plasmodium yoelli),스트렙토코커스 소브리누스(Streptococcus sobrinus),시겔라 플렉스네리(Shigella flexneri),RSV, 플라스모듐 엔타모에바 히스톨리티카(Plasmodium Entamoeba histolytica),쉬스토소마 자포니쿰(Schistosoma japonicum),쉬스토소마 만소니(Schistosoma mansoni),소의 인히빈 및 에볼라 바이러스로 이루어진 그룹 중에서 선택된 병원체에 존재하는 아미노산 서열인 재조합 HBc 키머 단백질 분자.
- 제43항에 있어서, 위치 150에서부터 C-말단까지의 HBc와 이종인 서열이 HBc 잔기 140-149 중의 하나와 펩티드-결합된 T 세포 에피토프인 재조합 HBc 키머 단백질 분자.
- 제48항에 있어서, T 세포 에피토프가, 고려된 키머가 면역원으로서 사용될 유기체로부터 유래되는 재조합 HBc 키머 단백질 분자.
- 제43항에 있어서, C-말단 시스테인 잔기가 키머 단백질 분자의 C-말단의 약 5개 아미노산 잔기 내에 위치하는 재조합 HBc 키머 단백질 분자.
- 재조합 B형 간염 코어(HBc) 키머 단백질 분자로 구성되고, 이러한 키머 단백질이 (i) N-말단, HBc 면역원성 루프 또는 C-말단에 하나 이상의 면역원성 에피토프를 표시하거나 또는 (ii) 상기 HBc 면역원성 루프 내의 접합된 에피토프에 대한 이종 링커 잔기를 갖고, C-말단 또는 C-말단 근처에 시스테인 잔기를 함유하며; 또한 상기 시스테인 잔기가 없으며 그 밖에는 동일한 단백질로 구성된 입자에 비해 안정성이 증강되고 핵산과 실질적으로 결합하지 않는, 면역원성 입자.
- 제51항에 있어서, 280/260 흡광도 비가 약 1.2 내지 약 1.7인 면역원성 입자.
- 제51항에 있어서, 재조합 HBc 키머 단백질이 N-말단에서 면역원성 에피토프를 표시하는 면역원성 입자.
- 제51항에 있어서, 재조합 HBc 키머 단백질이 C-말단에서 면역원성 에피토프를 표시하는 면역원성 입자.
- 제51항에 있어서, 재조합 HBc 키머 단백질이 면역원성 루프에서 면역원성 에피토프를 표시하는 면역원성 입자.
- 제51항에 있어서, 재조합 HBc 키머 단백질이 B 세포 면역원성 에피토프를 표시하는 면역원성 입자.
- 제51항에 있어서, 재조합 HBc 키머 단백질이 T 세포 면역원성 에피토프를 표시하는 면역원성 입자.
- 제51항에 있어서, 재조합 HBc 키머 단백질이 별도의 B 세포 및 T 세포 면역원성 에피토프를 표시하는 면역원성 입자.
- 제51항에 있어서, 재조합 HBc 키머 단백질이 HBc 면역원성 루프 내의 접합된 에피토프에 대한 이종 링커 잔기를 갖는 면역원성 입자.
- 제59항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기가 리신, 아스파르트산, 글루탐산, 시스테인 및 티로신 잔기로 이루어진 그룹 중에서 선택되는 면역원성 입자.
- 제60항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기가 합텐에 접합되는 면역원성 입자.
- 제61항에 있어서, 합텐이 올리고삭카라이드인 면역원성 입자.
- 다수의 재조합 키머 B형 간염 코어(HBc) 단백질 분자로 구성되는데,이러한 재조합 키머 HBc 단백질 분자가 약 515개 이하의 아미노산 잔기 길이를 갖고,(a) HBc 면역우성 루프에 존재하는 접합된 에피토프에 대한 이종 링커 잔기 또는 펩티드-결합된 이종 에피토프를 포함하는 HBc 분자의 N-말단의 150개 아미노산 잔기중 약 130개 이상의 HBc 서열, 또는 N-말단의 150개 HBc 아미노산 잔기중 약 135개 이상의 잔기 서열을 함유하고,(b) HBc 서열의 C-말단 잔기로부터 상기 분자의 C-말단을 향하고 있고 키머분자의 C-말단으로부터 약 30개 잔기 이내에 존재하는 1 내지 10개의 시스테인 잔기[C-말단 시스테인 잔기(들)]를 함유하며,(c) HBc 위치 135에서부터 HBc C-말단까지의 6개 이상의 아미노산 잔기 서열을 함유하며,또한, 상기 키머 분자가 HBc 서열 내의 10% 이하의 보존적으로 치환된 아미노산 잔기를 함유하고;핵산과 실질적으로 결합하지 않으며, 상기 C-말단 시스테인 잔기(들)가 결여되고 그 밖에는 동일한 HBc 키머로부터 형성된 입자 보다 더 안정적이거나 또는 키머 분자에 존재하는 하나의 C-말단 시스테인 잔기가 또 다른 잔기로 대체된 경우 보다 더 안정적이고, 또한 아미노산 잔기의 약 20% 이하가 상기 키머의 HBc 서열에서 치환된 아미노산 잔기 서열을 갖는, 면역원성 입자.
- 제63항에 있어서, 280nm 대 260nm에서의 흡광도 비가 약 1.4 내지 약 1.6인 면역원성 입자.
- 제63항에 있어서, 재조합 키머 HBc 단백질 분자의 길이가 약 175 내지 약 240개 아미노산 잔기인 면역원성 입자.
- 제63항에 있어서, 접합된 에피토프에 대한 이종 링커 잔기 또는 펩티드-결합된 이종 에피토프가 이종 에피토프인 면역원성 입자.
- 제66항에 있어서, 이종 에피토프가 B 세포 에피토프인 면역원성 입자.
- 제63항에 있어서, 재조합 키머 HBc 단백질 분자의 길이가 약 435개 이하의 아미노산 잔기인 면역원성 입자.
- 제63항에 있어서, HBc의 아미노산 잔기 1-4 중의 하나와 펩티드-결합된 제2의 이종 에피토프를 함유하는 면역원성 입자.
- 제68항에 있어서, B 세포 에피토프가 HBc 서열 내의 아미노산 잔기 76 내지 85의 위치에서 펩티드-결합되고, 위치 76에서부터 85까지의 HBc 서열의 5개 이상 잔기가 존재하는 면역원성 입자.
- 제70항에 있어서, B 세포 에피토프에 의해 중단된 아미노산 잔기 76 내지 85의 HBc 서열이 존재하는 면역원성 입자.
- 제68항에 있어서, 펩티드-결합된 이종 T 세포 에피토프를 추가로 포함하는 면역원성 입자.
- 제72항에 있어서, T 세포 에피토프가 C-말단 HBc 아미노산 잔기에 펩티드-결합되는 면역원성 입자.
- 제73항에 있어서, C-말단 시스테인 잔기(들)가 HBc 키머 단백질 분자의 C-말단의 5개 아미노산 잔기 내에 존재하는 면역원성 입자.
- 제63항에 있어서, 재조합 키머 HBc 단백질 분자가 약 135 내지 약 515개 아미노산 잔기 길이를 갖고, 도메인 I, II, III 및 IV로 명명된, N-말단으로부터 4개의 펩티드-연결된 아미노산 잔기 서열 도메인을 함유하며, 이때,(a) 도메인 I은 약 71 내지 약 100개 아미노산 잔기를 포함하는데, 이의 서열에는 적어도 HBc의 위치 5에서부터 위치 75까지의 잔기 서열이 포함되고, HBc 잔기 1-4 중의 하나와 펩티드-결합된 약 30개 이하의 아미노산 잔기를 함유하는 이종 에피토프가 임의로 포함되고;(b) 도메인 II는 도메인 I의 HBc 잔기 75와 펩티드-결합된 약 5 내지 약 250개 아미노산 잔기를 포함하는데, 여기서 (i) HBc 위치 76에서부터 85까지의 서열 내의 0 내지 모든 잔기는, HBc와 이종이고 접합된 에피토프에 대한 이종 링커 잔기 또는 이종 에피토프를 구성하는 1 내지 약 245개 아미노산 잔기와 펩티드-결합되어 존재하거나, 또는 (ii) 위치 76 내지 85에서의 HBc 서열에는 이종 잔기가 존재하지 않으며;(c) 도메인 III은 도메인 II의 잔기 85와 펩티드-결합된 위치 86에서부터 위치 135까지의 HBc 서열이고;(d) 도메인 IV는 (i) 도메인 III의 위치 135의 잔기와 펩티드-결합된 위치 136에서부터 149까지의 HBc 아미노산 잔기 서열의 0 내지 14개 잔기, (ii) 키머 분자의 C-말단으로부터 약 30개 잔기 이내의 1 내지 10개의 시스테인 잔기[C-말단 시스테인 잔기(들)], 및 (iii) 위치 150에서부터 C-말단까지의 HBc와 이종인 서열 내의 0 내지 약 100개 아미노산 잔기를 포함하는데, 단 도메인 IV는 상기 (ii)의 1 내지 10개 시스테인 잔기를 포함한 6개 이상의 아미노산 잔기를 함유하고;또한 상기 키머 HBc 단백질이, 아미노산 잔기의 약 10% 이하가 키머의 HBc 서열에서 치환된 아미노산 잔기 서열을 갖는, 면역원성 입자.
- 제75항에 있어서, 도메인 II 내의 접합된 에피토프에 대한 이종 링커 잔기를 함유하고 이러한 이종 링커 잔기에 연결된 합텐을 추가로 포함하는 면역원성 입자.
- 제76항에 있어서, 합텐이 B 세포 면역원인 면역원성 입자.
- 제63항에 있어서, 재조합 키머 HBc 단백질 분자가 약 175 내지 약 240개 아미노산 잔기 길이를 갖고, 도메인 I, II, III 및 IV로 명명된, N-말단으로부터 4개의 펩티드-연결된 아미노산 잔기 서열 도메인을 함유하며, 이때(a) 도메인 I은 대략 HBc의 위치 1에서부터 위치 75까지의 잔기 서열을 포함하고;(b) 도메인 II는 도메인 I의 HBc 잔기 75와 펩티드-결합된 약 5 내지 약 55개 아미노산 잔기를 포함하는데, 여기서 HBc 위치 76에서부터 85까지의 서열 내의 4개 이상의 잔기가, HBc와 이종이며 이종 에피토프를 구성하는 6 내지 약 50개 아미노산 잔기와 펩티드-결합되어 존재하고;(c) 도메인 III은 도메인 II의 잔기 85와 펩티드-결합된 위치 86에서부터 위치 135까지의 HBc 서열이고;(d) 도메인 IV는 (i) 도메인 III의 위치 135의 잔기와 펩티드-결합된 위치 136에서부터 149까지의 HBc 아미노산 잔기 서열의 5 내지 14개 잔기, (ii) 키머 분자의 C-말단으로부터 약 30개 잔기 이내의 1 내지 약 5개의 시스테인 잔기[C-말단 시스테인 잔기], 및 (iii) 위치 150에서부터 C-말단까지의 HBc와 이종인 서열 내의 0 내지 약 50개 아미노산 잔기를 포함하고,또한 상기 키머 HBc 단백질이 아미노산 잔기의 약 5% 이하가 HBc 서열에서 치환된 아미노산 잔기 서열을 갖는, 약 1.4 내지 약 1.6의 280nm 대 260nm의 흡광도 비를 나타내는 면역원성 입자.
- 약제학적으로 허용되는 희석제에 용해 또는 분산된 면역원성 입자의 면역원성 유효량을 포함하며, 이때상기 면역원성 입자가 다수의 재조합 키머 B형 간염 코어(HBc) 단백질 분자로 구성되고, 이러한 재조합 키머 HBc 단백질 분자가 약 515개 이하의 아미노산 잔기 길이를 갖고,(a) HBc 면역우성 루프에 존재하는 접합된 에피토프에 대한 이종 링커 잔기또는 펩티드-결합된 이종 에피토프를 포함하는 HBc 분자의 N-말단의 150개 아미노산 잔기중 약 130개 이상의 HBc 서열, 또는 N-말단의 150개 HBc 아미노산 잔기중 약 135개 이상의 잔기 서열을 함유하고,(b) HBc 서열의 C-말단 잔기로부터 상기 분자의 C-말단을 향하고 있고 키머 분자의 C-말단으로부터 약 30개 잔기 이내에 존재하는 1 내지 10개의 시스테인 잔기[C-말단 시스테인 잔기(들)]를 함유하며,(c) HBc 위치 135에서부터 HBc C-말단까지의 6개 이상의 아미노산 잔기 서열을 함유하고,또한 상기 키머 분자가 HBc 서열 내의 20% 이하의 보존적으로 치환된 아미노산 잔기를 함유하고;상기 입자가 핵산과 실질적으로 결합하지 않으며, 상기 C-말단 시스테인 잔기(들)가 결여되고 그 밖에는 동일한 HBc 키머로부터 형성된 입자 보다 더 안정적이거나 또는 키머 분자에 존재하는 하나의 C-말단 시스테인 잔기가 또 다른 잔기로 대체된 경우 보다 더 안정적인, 백신 또는 접종원.
- 제79항에 있어서, 재조합 키머 HBc 단백질 분자가 약 135 내지 약 515개 아미노산 잔기 길이를 갖고, 도메인 I, II, III 및 IV로 명명된, N-말단으로부터 4개의 펩티드-연결된 아미노산 잔기 서열 도메인을 함유하며, 이때(a) 도메인 I은 약 71 내지 약 100개 아미노산 잔기를 포함하는데, 이의 서열에는 적어도 HBc의 위치 5에서부터 위치 75까지의 잔기 서열이 포함되고, HBc 잔기 1-4 중의 하나와 펩티드-결합된 약 30개 이하의 아미노산 잔기를 함유하는 이종 에피토프가 임의로 포함되고;(b) 도메인 II는 도메인 I의 HBc 잔기 75와 펩티드-결합된 약 5 내지 약 250개 아미노산 잔기를 포함하는데, 여기서 (i) HBc 위치 76에서부터 85까지의 서열 내의 4개 이상의 잔기가, HBc와 이종이며 접합된 에피토프에 대한 이종 링커 잔기 또는 이종 에피토프를 구성하는 1 내지 약 245개 아미노산 잔기와 펩티드-결합되어 존재하거나, 또는 (ii) 위치 76 내지 85에서의 HBc 서열에는 이종 잔기가 존재하지 않으며;(c) 도메인 III은 도메인 II의 잔기 85와 펩티드-결합된 위치 86에서부터 위치 135까지의 HBc 서열이고;(d) 도메인 IV는 (i) 도메인 III의 위치 135의 잔기와 펩티드-결합된 위치 136에서부터 149까지의 HBc 아미노산 잔기 서열의 0 내지 14개 잔기, (ii) 키머 분자의 C-말단으로부터 약 30개 잔기 이내의 1 내지 10개의 시스테인 잔기[C-말단 시스테인 잔기(들)], 및 (iii) 위치 150에서부터 C-말단까지의 HBc와 이종인 서열 내의 0 내지 약 100개 아미노산 잔기를 포함하는데, 단 도메인 IV는 상기 (ii)의 1 내지 10개 시스테인 잔기를 포함한 6개 이상의 아미노산 잔기를 함유하고;상기 재조합 키머 HBc 단백질이, 아미노산 잔기의 약 5% 이하가 HBc 서열에서 치환된 아미노산 잔기 서열을 갖는, 백신 또는 접종원.
- 제80항에 있어서, 도메인 II 내의 접합된 에피토프에 대한 이종 링커 잔기를함유하고 이러한 이종 링커 잔기에 연결된 합텐을 추가로 포함하는 백신 또는 접종원.
- 제79항에 있어서, 재조합 키머 HBc 단백질 분자가 약 175 내지 약 240개 아미노산 잔기 길이를 갖고, 도메인 I, II, III 및 IV로 명명된, N-말단으로부터 4개의 펩티드-연결된 아미노산 잔기 서열 도메인을 함유하며, 이때(a) 도메인 I은 대략 HBc의 위치 1에서부터 위치 75까지의 잔기 서열을 포함하고;(b) 도메인 II는 도메인 I의 HBc 잔기 75와 펩티드-결합된 약 5 내지 약 55개 아미노산 잔기를 포함하는데, 여기서 HBc 위치 76에서부터 85까지의 서열 내의 4개 이상의 잔기가, HBc와 이종이며 이종 에피토프를 구성하는 6 내지 약 50개 아미노산 잔기와 펩티드-결합되어 존재하고;(c) 도메인 III은 도메인 II의 잔기 85와 펩티드-결합된 위치 86에서부터 위치 135까지의 HBc 서열이고;(d) 도메인 IV는 (i) 도메인 III의 위치 135의 잔기와 펩티드-결합된 위치 136에서부터 149까지의 HBc 아미노산 잔기 서열의 5 내지 14개 잔기; 및 (ii) 위치 150에서부터 C-말단까지의 HBc와 이종인 서열 내의 0 내지 약 50개 아미노산 잔기를 포함하며;상기 입자가 약 1.4 내지 약 1.6의 280nm 대 260nm의 흡광도 비를 나타내는, 백신 또는 접종원.
- 제79항에 있어서, 비경구 투여용으로 적응시킨 백신 또는 접종원.
- 제79항에 있어서, 점막성 면역용으로 적응시킨 백신 또는 접종원.
- 제79항에 있어서, 재조합 키머 HBc 단백질 분자 입자가 에스. 티피, 에스. 티피무륨 또는 에스. 티피무륨-이. 콜라이 하이브리드의 약독화 균주 내에 존재하는 백신 또는 접종원.
- 제79항에 있어서, 재조합 키머 HBc 단백질 분자 입자가 식물 조직 내에 존재하는 백신 또는 접종원.
- 제79항에 있어서, 애쥬반트를 추가로 포함하는 백신 또는 접종원.
- 제87항에 있어서, 애쥬반트가 명반인 백신 또는 접종원.
- 제87항에 있어서, 애쥬반트가 무라밀 디펩티드, 7-치환된-8-옥소- 또는 8-설포-구아노신 유도체, 모노포스포릴 지질 A, 알루미늄 또는 칼슘 염으로 이루어진 그룹 중에서 선택된 작은 분자인 백신 또는 접종원.
- 제87항에 있어서, 애쥬반트가, 면역원성 입자 및 약제학적으로 허용되는 희석제로 유화시킨 오일인 백신 또는 접종원.
- 제90항에 있어서, 에멀션이 수 상과 오일 상을 갖는 유중수 에멀션인 백신 또는 접종원.
- 제90항에 있어서, 에멀션이 수 상과 오일 상을 갖는 수중유 에멀션인 백신 또는 접종원.
- 제92항에 있어서, 에멀션의 오일 상이 스쿠알렌을 포함하는 백신 또는 접종원.
- 제92항에 있어서, 에멀션의 오일 상이 스쿠알란을 포함하는 백신 또는 접종원.
- 제90항에 있어서, 에멀션의 수 상 및 오일 상이, 솔비탄 또는 만니드 C12-C24지방산 에스테르인 유화제에 의해 유화된 백신 또는 접종원.
- 제95항에 있어서, 유화제가 만니드 C12-C24지방산 에스테르인 백신 또는 접종원.
- 제96항에 있어서, 만니드 C12-C24지방산 에스테르의 C12-C24지방산이 올레산인 백신 또는 접종원.
- 제1항에 따르는 재조합 HBc 단백질 분자를 암호화하는 핵산, 또는 이의 변이체, 유사체 또는 상보체.
- 제18항에 따르는 재조합 HBc 단백질 분자를 암호화하는 핵산, 또는 이의 변이체, 유사체 또는 상보체.
- 제42항에 따르는 재조합 HBc 단백질 분자를 암호화하는 핵산, 또는 이의 변이체, 유사체 또는 상보체.
- 적합(compatible) 숙주 유기체에서 해당 유전자의 발현을 유도하기에 적합한 프로모터, 및 제1항에 따르는 재조합 HBc 단백질 분자를 암호화하는 유전자, 또는 이의 변이체, 유사체 또는 상보체를 한정하는 핵산 세그먼트에 작동적으로 연결된 벡터를 포함하는 재조합 핵산 분자.
- 적합 숙주 유기체에서 해당 유전자의 발현을 유도하기에 적합한 프로모터, 및 제18항에 따르는 재조합 HBc 단백질 분자를 암호화하는 유전자, 또는 이의 변이체, 유사체 또는 상보체를 한정하는 핵산 세그먼트에 작동적으로 연결된 벡터를 포함하는 재조합 핵산 분자.
- 적합 숙주 유기체에서 해당 유전자의 발현을 유도하기에 적합한 프로모터, 및 제42항에 따르는 재조합 HBc 단백질 분자를 암호화하는 유전자, 또는 이의 변이체, 유사체 또는 상보체를 한정하는 핵산 세그먼트에 작동적으로 연결된 벡터를 포함하는 재조합 핵산 분자.
- 제101항에 따르는 재조합 핵산 분자로 형질전환시킨 숙주 세포.
- 제104항에 있어서, 숙주 세포가 CHO, VERO 또는 COS 세포, 이. 콜라이, 에스. 세레비지애, 피치아 파스토리스 티피, 에스. 티피무륨 및 에스. 티피무륨-이. 콜라이 하이브리드로 이루어진 그룹 중에서 선택되는, 형질전환된 숙주 세포.
- 제102항에 따르는 재조합 핵산 분자로 형질전환시킨 숙주 세포.
- 제106항에 있어서, 숙주 세포가 CHO, VERO 또는 COS 세포, 이. 콜라이, 에스. 세레비지애, 피치아 파스토리스 티피, 에스. 티피무륨 및 에스. 티피무륨-이.콜라이 하이브리드로 이루어진 그룹 중에서 선택되는, 형질전환된 숙주 세포.
- 제102항에 따르는 재조합 핵산 분자로 형질전환시킨 숙주 세포.
- 제108항에 있어서, 숙주 세포가 CHO, VERO 또는 COS 세포, 이. 콜라이, 에스. 세레비지애, 피치아 파스토리스 티피, 에스. 티피무륨 및 에스. 티피무륨-이. 콜라이 하이브리드로 이루어진 그룹 중에서 선택되는, 형질전환된 숙주 세포.
- 숙주 동물에게, 제79항에 따르는 백신 또는 접종원을 접종하는 단계; 및 이와 같이 접종된 동물이 면역 반응을 발생시키기에 충분한 시간 동안 당해 동물을 유지시키는 단계를 포함하여, 접종된 숙주 동물에게서 면역 반응을 유도하는 방법.
- 숙주 동물에게, 제80항에 따르는 백신 또는 접종원을 접종하는 단계; 및 이와 같이 접종된 동물이 면역 반응을 발생시키기에 충분한 시간 동안 당해 동물을 유지시키는 단계를 포함하여, 접종된 숙주 동물에게서 면역 반응을 유도하는 방법.
- 숙주 동물에게, 제82항에 따르는 백신 또는 접종원을 접종하는 단계; 및 이와 같이 접종된 동물이 면역 반응을 발생시키기에 충분한 시간 동안 당해 동물을 유지시키는 단계를 포함하여, 접종된 숙주 동물에게서 면역 반응을 유도하는 방법.
- 숙주 동물에게, 제87항에 따르는 백신 또는 접종원을 접종하는 단계; 및 이와 같이 접종된 동물이 면역 반응을 발생시키기에 충분한 시간 동안 당해 동물을 유지시키는 단계를 포함하여, 접종된 숙주 동물에게서 면역 반응을 유도하는 방법.
- 숙주 동물에게, 제88항에 따르는 백신 또는 접종원을 접종하는 단계; 및 이와 같이 접종된 동물이 면역 반응을 발생시키기에 충분한 시간 동안 당해 동물을 유지시키는 단계를 포함하여, 접종된 숙주 동물에게서 면역 반응을 유도하는 방법.
- 숙주 동물에게, 제92항에 따르는 백신 또는 접종원을 접종하는 단계; 및 이와 같이 접종된 동물이 면역 반응을 발생시키기에 충분한 시간 동안 당해 동물을 유지시키는 단계를 포함하여, 접종된 숙주 동물에게서 면역 반응을 유도하는 방법.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22584300P | 2000-08-16 | 2000-08-16 | |
US60/225,843 | 2000-08-16 | ||
US22686700P | 2000-08-22 | 2000-08-22 | |
US60/226,867 | 2000-08-22 | ||
US09/930,915 | 2001-08-15 | ||
US09/930,915 US20030138769A1 (en) | 2000-08-16 | 2001-08-15 | Immunogenic HBc chimer particles having enhanced stability |
PCT/US2001/041759 WO2002014478A2 (en) | 2000-08-16 | 2001-08-16 | IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030084887A true KR20030084887A (ko) | 2003-11-01 |
Family
ID=27397530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-7002259A KR20030084887A (ko) | 2000-08-16 | 2001-08-16 | 안정성이 증강된 면역원성 HBc 키머 입자 |
Country Status (12)
Country | Link |
---|---|
US (3) | US20030138769A1 (ko) |
EP (1) | EP1333857A4 (ko) |
JP (2) | JP2005517380A (ko) |
KR (1) | KR20030084887A (ko) |
AP (1) | AP2003002752A0 (ko) |
AU (2) | AU2001285452B2 (ko) |
BR (1) | BR0113307A (ko) |
CA (1) | CA2420037A1 (ko) |
EA (1) | EA006207B1 (ko) |
MX (1) | MXPA03001338A (ko) |
OA (1) | OA12366A (ko) |
WO (1) | WO2002014478A2 (ko) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6942866B2 (en) | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
MXPA04002644A (es) | 2001-10-05 | 2004-07-08 | Cytos Biotechnology Ag | Conjugados que portan un peptido de angiotensina y usos de los mismos. |
AT410666B (de) * | 2001-12-11 | 2003-06-25 | Intercell Biomedizinische Forschungs & Entwicklungs Gmbh | Nukleinsäure bindende peptide und die verwendung derartiger peptide in pharmazeutischen präparaten |
AU2003213168A1 (en) * | 2002-02-21 | 2003-12-19 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
NZ537003A (en) | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
WO2004016282A1 (en) | 2002-07-19 | 2004-02-26 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
AU2003300841B2 (en) * | 2002-12-10 | 2008-03-20 | Lorantis Ltd. | Stabilized immunogenic HBc chimer particles |
WO2004084940A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
US7144712B2 (en) * | 2003-07-30 | 2006-12-05 | Vaccine Research Institute Of San Diego | Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
AU2004260665B2 (en) * | 2003-07-30 | 2007-11-15 | Vlp Biotech, Inc. | Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
US7408075B1 (en) * | 2005-03-23 | 2008-08-05 | The United States Of America As Represented By The Department Of Health And Human Services | Synthesis of phosphocholine ester derivatives and conjugates thereof |
US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
BRPI0714721A2 (pt) | 2006-07-14 | 2013-04-24 | Sanofi Pasteur Biologics Co | construÇço de vacinas de vÍrus recombinante por inserÇço direta mediada por transpàson de determinantes imunolàgicos estranhos em proteÍnas de vÍrus vetorial |
EP1897887A1 (de) * | 2006-09-08 | 2008-03-12 | Universitätsklinikum Freiburg | Split-Core-Partikel für die Präsentation von Fremdmolekülen, insbesondere für Impfstoffanwendungen und Verfahren zu deren Herstellung |
WO2008100290A2 (en) | 2006-09-29 | 2008-08-21 | Sanofi Pasteur Biologics Co | Recombinant rhinovirus vectors |
KR20090092764A (ko) | 2006-09-29 | 2009-09-01 | 사노피 파스테르 바이오로직스 씨오 | 신규한 리노바이러스 중화 면역원 및 이의 백신 용도로의 이용 |
EP1920781B1 (en) * | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
KR100861923B1 (ko) * | 2006-12-07 | 2008-10-09 | 메디칸(주) | 바이러스 항원 발현 재조합 벡터로 형질전환된 곤충세포를 이용한 a형 간염 바이러스 항원의 제조방법 |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
ITUD20080055A1 (it) * | 2008-03-13 | 2009-09-14 | Transactiva S R L | Procedimento per la produzione di una proteina umana in pianta, in particolare un enzima lisosomiale umano ricombinante in endosperma di cereali |
US10485879B2 (en) | 2008-04-15 | 2019-11-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues |
NZ592977A (en) | 2008-12-09 | 2013-01-25 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
NZ618391A (en) | 2009-07-30 | 2015-07-31 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Pcsk9 백신 |
EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
WO2012082803A2 (en) * | 2010-12-13 | 2012-06-21 | Cel-Sci Corporation | Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof |
PT2672992T (pt) | 2011-02-11 | 2020-07-27 | Univ Pennsylvania | Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
EP2698164B1 (en) | 2011-04-15 | 2018-04-04 | Osaka University | Dna vaccine |
WO2012162564A1 (en) | 2011-05-25 | 2012-11-29 | Cel-Sci Corporation | Method for inducing an immune response and formulations thereof |
SI2717898T1 (sl) * | 2011-06-10 | 2019-07-31 | Bioverativ Therapeutics Inc. | Spojine prokoagulantov in metode za njihovo uporabo |
WO2014034735A1 (ja) | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Vegf及び/又はアンギオポエチン-2の特異的エピトープを含むdnaワクチン |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
CN111925423B (zh) * | 2014-11-07 | 2022-08-19 | 普莱柯生物工程股份有限公司 | 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用 |
WO2019008001A1 (en) | 2017-07-04 | 2019-01-10 | Curevac Ag | NEW NUCLEIC ACID MOLECULES |
JP2021501572A (ja) | 2017-10-19 | 2021-01-21 | キュアバック アーゲー | 新規な人工核酸分子 |
TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
CA3155202A1 (en) | 2019-10-23 | 2021-04-29 | Arthur M. Krieg | Synthetic rig-i-like receptor agonists |
CN113943075A (zh) * | 2020-07-15 | 2022-01-18 | 湖南怡田美农业科技有限公司 | 一种剑麻皂素提取后的污染处理方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767842A (en) * | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
US5614194A (en) * | 1981-02-12 | 1997-03-25 | New York University | Protective peptide antigen |
US4888170A (en) * | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
US4643992A (en) * | 1982-11-09 | 1987-02-17 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US4539205A (en) * | 1982-11-09 | 1985-09-03 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US4987237A (en) * | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
US5093318A (en) * | 1983-11-01 | 1992-03-03 | Scripps Clinic And Research Foundation | Immunostimulating guanosine derivatives and their pharmaceutical compositions |
US5011828A (en) * | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US4882145A (en) * | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4818527A (en) * | 1986-12-09 | 1989-04-04 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4886782A (en) * | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
EP0433372B1 (en) * | 1988-09-06 | 2002-06-12 | Washington University | Oral immunization by transgenic plants |
US5023179A (en) * | 1988-11-14 | 1991-06-11 | Eric Lam | Promoter enhancer element for gene expression in plant roots |
US5110732A (en) * | 1989-03-14 | 1992-05-05 | The Rockefeller University | Selective gene expression in plants |
NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
DE69132769T2 (de) * | 1990-03-02 | 2002-04-18 | Bp Corp North America Inc | Biosynthese von carotinoiden in genetisch hergestellten wirtszellen |
US5618988A (en) * | 1990-03-02 | 1997-04-08 | Amoco Corporation | Enhanced carotenoid accumulation in storage organs of genetically engineered plants |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
US5928902A (en) * | 1992-02-27 | 1999-07-27 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBsAg |
US5297441A (en) * | 1992-08-14 | 1994-03-29 | The Boeing Company | Apparatus for supporting a test specimen for compression testing |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
ATE215385T1 (de) * | 1997-12-16 | 2002-04-15 | Chiron Corp | Verwendung von mikropartikeln mit submikron öl/wasser emulsionen |
AU767144B2 (en) * | 1998-02-12 | 2003-10-30 | Apovia, Inc. | Strategically modified hepatitis B core proteins and their derivatives |
US5990085A (en) * | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
WO2001085208A2 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
-
2001
- 2001-08-15 US US09/930,915 patent/US20030138769A1/en not_active Abandoned
- 2001-08-16 KR KR10-2003-7002259A patent/KR20030084887A/ko active Search and Examination
- 2001-08-16 JP JP2002519606A patent/JP2005517380A/ja active Pending
- 2001-08-16 AP APAP/P/2003/002752A patent/AP2003002752A0/en unknown
- 2001-08-16 BR BR0113307-1A patent/BR0113307A/pt not_active IP Right Cessation
- 2001-08-16 EP EP01964615A patent/EP1333857A4/en not_active Withdrawn
- 2001-08-16 CA CA002420037A patent/CA2420037A1/en not_active Abandoned
- 2001-08-16 WO PCT/US2001/041759 patent/WO2002014478A2/en active Application Filing
- 2001-08-16 AU AU2001285452A patent/AU2001285452B2/en not_active Ceased
- 2001-08-16 EA EA200300270A patent/EA006207B1/ru not_active IP Right Cessation
- 2001-08-16 AU AU8545201A patent/AU8545201A/xx active Pending
- 2001-08-16 OA OA1200300045A patent/OA12366A/en unknown
- 2001-08-16 MX MXPA03001338A patent/MXPA03001338A/es not_active Application Discontinuation
-
2004
- 2004-03-22 US US10/806,006 patent/US20040152876A1/en not_active Abandoned
- 2004-03-22 US US10/805,913 patent/US20040156864A1/en not_active Abandoned
-
2012
- 2012-04-09 JP JP2012088679A patent/JP2012139237A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU8545201A (en) | 2002-02-25 |
JP2005517380A (ja) | 2005-06-16 |
AP2003002752A0 (en) | 2003-06-30 |
MXPA03001338A (es) | 2004-01-26 |
EP1333857A4 (en) | 2006-02-22 |
WO2002014478A3 (en) | 2003-06-05 |
EA006207B1 (ru) | 2005-10-27 |
US20040152876A1 (en) | 2004-08-05 |
JP2012139237A (ja) | 2012-07-26 |
US20040156864A1 (en) | 2004-08-12 |
BR0113307A (pt) | 2005-06-28 |
US20030138769A1 (en) | 2003-07-24 |
WO2002014478A2 (en) | 2002-02-21 |
AU2001285452B2 (en) | 2006-11-02 |
CA2420037A1 (en) | 2002-02-21 |
EA200300270A1 (ru) | 2004-04-29 |
OA12366A (en) | 2006-05-17 |
EP1333857A2 (en) | 2003-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20030084887A (ko) | 안정성이 증강된 면역원성 HBc 키머 입자 | |
US6942866B2 (en) | Malaria immunogen and vaccine | |
AU2001285452A1 (en) | Immunogenic HBc chimer particles having enhanced stability | |
KR100815408B1 (ko) | 만성 간염용 치료 백신으로서의 안정화된 HBc 키메라입자 | |
JP2012056954A (ja) | 安定化させた免疫原性HBcキメラ粒子 | |
JP2002509700A (ja) | 戦略的修飾されたb型肝炎コアタンパク質及びそれらの誘導体 | |
US20100183652A1 (en) | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS | |
US20070015199A1 (en) | Stabilized immunogenic HBc chimer particles | |
US20030202982A1 (en) | Influenza immunogen and vaccine | |
US20030175863A1 (en) | Influenza immunogen and vaccine | |
US20030185858A1 (en) | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine | |
WO2003072731A2 (en) | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS | |
CN101052414B (zh) | 具有增强的稳定性的免疫原性HBc嵌合体颗粒 | |
WO2003072722A2 (en) | IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
N231 | Notification of change of applicant | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E801 | Decision on dismissal of amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090504 Effective date: 20101029 Free format text: TRIAL NUMBER: 2009101004114; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090504 Effective date: 20101029 |
|
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 2011201000132; APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110104 Effective date: 20111012 Free format text: TRIAL NUMBER: 2011201000132; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110104 Effective date: 20111012 |